Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

X
Trial Profile

A Randomized, Multi-Center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glibenclamide (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms GAMES-RP
  • Sponsors Biogen
  • Most Recent Events

    • 20 Sep 2019 Results published in the Stroke
    • 08 Feb 2019 Results assessing the effect of Glibenclamide on Water Uptake and Mass Effect in Large Hemispheric Infarction, presented at the International Stroke Conference 2019
    • 22 May 2018 Results (n=86) efficacy and tolerability of glibenclamide [CIRARA; Remedy Pharmaceuticals] in patients with a severe anterior circulation ischaemic stroke who are likely to develop malignant oedema, were published in the Stroke.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top